The combined global market size of medical conditions we target exceeds US$400B per annum. This potential addressable market is calculated by combining the treatment markets of OSA, TBI, concussion, rheumatoid arthritis, inflammatory bowel disease, inflammatory lung conditions (ARDS, COPD, Asthma, Bronchitis) and generalised anxiety disorder (GAD). Success in the clinical development programmes will not only provide benefit to patients, but also offer significant economic potential for our shareholders.
Clinical Development Pathway
Incannex is a medicinal cannabinoid and psychedelic therapy development company, undertaking phase 2 clinical trials guided by its extended team, post liaison with FDA. With 3 leading drug candidates and a diverse portfolio of 28 distinct research and development programs, and 6 clinical trials underway, our programs target conditions for patients with unmet medical needs. This means we have an opportunity to treat a significant number of people – the potential is limitless.
Discover where you can participate in our leading clinical trials
US$400B market potential.
Latest results and presentations
Subscribe and stay connected
Stay up to date with Incannex’s leading research and development programs, multiple secondary assets, investor relations and biotechnology advancements.
"*" indicates required fields